Involved-Node Radiotherapy and Modern Radiation Treatment Techniques in Patients With Hodgkin Lymphoma

Paumier, A.; Ghalibafian, Mithra; Beaudré, A.; Ferreira, I.; Pichenot, C.; Messaï, T.; Lessard, N.; Lefkopoulos, Dimitri; Girinsky, T.

doi:10.1016/j.ijrobp.2010.09.007

Cited by 68 publications

(35 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to cardiac doses, dose or volume dependence for late toxicity remains unclear [29]. Other studies [18,24] have also included the proximal coronary arteries as a possible region that may relate to late complications; we were not able to reliably contour this region with our scan data/phase of contrast/experience. Campbell et al [18] found that although INRT offered a reduction in whole heart doses, the dose to proximal coronary arteries was not reduced.…”

Section: Discussionmentioning

confidence: 97%

Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks

et al. 2015

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks

et al. 2015

View full text Add to dashboard Cite

“…In such cases, five‐year overall survival is expected to approach approximately 95% (2) . However, it is now well established that, in the longer term, these patients are at risk for thoracic radiotherapy treatment‐related death, in particular due to cardiovascular events and secondary malignancies 3 , 4 , 5 . Cause‐specific mortality studies of patients with HL note secondary malignancy and cardiovascular failure as the second and third leading causes of death, respectively, after death due to HL (3) .…”

Section: Introductionmentioning

confidence: 99%

“…Radiotherapy techniques and modalities providing greater normal tissue sparing may reduce the risks for cardiac mortality and secondary cancers 4 , 8 , 11 , 12 . Biological modeling using follow‐up information from patients receiving radiotherapy offers a method of interpreting the dose‐volume data of treatment plans to predict outcomes 13 , 14 .…”

Section: Introductionmentioning

confidence: 99%

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential

Toltz

Shin

Mitrou

et al. 2015

J Applied Clin Med Phys

View full text Add to dashboard Cite

In 2010, all young patients treated for intrathoracic Hodgkin lymphoma (HL) at one of 10 radiotherapy centers in the province of Quebec received 3D conformal photon therapy. These patients may now be at risk for late effects of their treatment, notably secondary malignancies and cardiac toxicity. We hypothesized that more complex radiotherapy, including intensity‐modulated proton therapy (IMPT) and possibly IMRT (in the form of helical tomotherapy (HT)), could benefit these patients. With institutional review board approval at 10 institutions, all treatment plans for patients under the age of 30 treated for HL during a six‐month consecutive period of 2010 were retrieved. Twenty‐six patients were identified, and after excluding patients with extrathoracic radiation or treatment of recurrence, 20 patients were replanned for HT and IMPT. Neutron dose for IMPT plans was estimated from published measurements. The relative seriality model was used to predict excess risk of cardiac mortality. A modified linear quadratic model was used to predict the excess absolute risk for induction of lung cancer and, in female patients, breast cancer. Model parameters were derived from published data. Predicted risk for cardiac mortality was similar among the three treatment techniques (absolute excess risk of cardiac mortality was not reduced for HT or IMPT (p>0.05,p>0.05) as compared to 3D CRT). Predicted risks were increased for HT and reduced for IMPT for secondary lung cancer (p<0.001,p<0.001) and breast cancers (p<0.001,p<0.001) as compared to 3D CRT.PACS numbers: 87.55.dh, 87.55.dk

show abstract

“…Importantly, initial data on the use of smaller field sizes have suggested that clinical outcomes are not sacrificed. Paumier et al, 20 for example, reported a 92% 5-year progression-free survival (PFS) in patients with early-stage HL treated with INRT as per EORTC-GELA guidelines. Similarly, Filippi et al 21 reported a 3-year relapse-free survival of 99% in patients with stage IIA disease using an ISRT technique.…”

mentioning

confidence: 99%

Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma

Narang

Terezakis

2015

J Natl Compr Canc Netw

View full text Add to dashboard Cite

The advent of effective combination chemotherapy markedly changed the management of Hodgkin lymphoma, establishing combined modality therapy as the standard of care for most patients with this disease. In response, significant interest has been shown in refining the delivery of radiation in the combined modality setting such that toxicity is minimized while still preserving disease control. An understanding of the way in which radiation treatment fields, prescription dose, and advanced technology have evolved to accomplish these goals is critical. Moreover, fluency in the clinical literature exploring contemporary questions, such as the omission of radiation and response-based treatment, is equally important. Knowledge of these topics will yield both an appreciation of the value of radiation in the combined modality setting and the ability to better customize treatment regimens to individual patients. (J Natl Compr Canc Netw 2015;13:597-605)

show abstract

Involved-Node Radiotherapy and Modern Radiation Treatment Techniques in Patients With Hodgkin Lymphoma

Cited by 68 publications

References 30 publications

Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks

Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks

Late radiation toxicity in Hodgkin lymphoma patients: proton therapy's potential

Contemporary Radiation Therapy in Combined Modality Therapy for Hodgkin Lymphoma

Contact Info

Product

Resources

About